Concurrent chemotherapy and short course radiotherapy in patients with stage IIIA to IIIB non-small cell lung cancer not eligible for radical treatment: Results of a randomized phase II study

Journal of Thoracic Oncology

Volumn 5, Issue 8, 2010, Pages 1255-1262

  Nawrocki, Sergiusz ^a,b   Krzakowski, MacIej ^c   Wasilewska Tesluk, Ewa ^a,b   Kowalski, Dariusz ^c   Rucinska, Monika ^a,b   Dziadziuszko, Rafal ^d   Sowa, Aleksander ^e  

^a ZOZ MSWiA z Warmi sko Mazurskim Centrum Onkologii   (Poland)

^b UNIVERSITY OF WARMIA AND MAZURY IN OLSZTYN   (Poland)

^c INSTITUTE OF ONCOLOGY   (Poland)

^d MEDICAL UNIVERSITY OF GDANSK   (Poland)

^e Orange Polska   (Poland)

Author keywords

Locally advanced non small cell lung cancer; Palliative chemoradiotherapy; Palliative radiotherapy

Indexed keywords

CISPLATIN; NAVELBINE;

ADULT; AGED; ANEMIA; ARTICLE; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CLINICAL EVALUATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DYSPNEA; ESOPHAGITIS; FEMALE; GASTROINTESTINAL SYMPTOM; HEMOPTYSIS; HUMAN; LUNG NON SMALL CELL CANCER; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUTROPENIA; PAIN; PANCYTOPENIA; PHASE 2 CLINICAL TRIAL; PRIMARY TUMOR; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; SURVIVAL TIME; SYMPTOMATOLOGY; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 77955097034     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181e15d33     Document Type: Article

References (21)

1. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-Small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899-909.
2. Auperin A, Le Pechoux C, Pignon JP, et al. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. Ann Oncol 2006;17:473-483.
3. Rowell NP, O'Rourke NP. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database of Syst Rev 2004;CD002140.
4. De Ruysscher D, Botterweck A, Dirx M, et al. Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study. Ann Oncol 2009;20:98-102.
5. Tomblyn MR, Rizzo JD. Are there circumstances in which phase 2 study results should be practice-changing? Hematology Am Soc Hematol Educ Program 2007:489-492.
6. Lee JJ, Feng L. Randomized phase II designs in cancer clinical trials: current status and future directions. J Clin Oncol 2005;23:4450-4457.
7. Rubinstein LV, Korn EL, Freidlin B, et al. Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol 2005;23:7199-7206.
8. Brundage MD, Bezjak A, Dixon P, et al. The role of palliative thoracic radiotherapy in non-small cell lung cancer. Can J Oncol 1996;6(suppl 1):25-32.
9. Konski A, Feigenberg S, Chow E. Palliative radiation therapy. Semin Oncol 2005;32:156-164.
10. Rees GJ, Devrell CE, Barley VL, et al. Palliative radiotherapy for lung cancer: two versus five fractions. Clin Oncol (R Coll Radiol) 1997;9: 90-95.
11. Macbeth F, Toy E, Coles B, et al. Palliative radiotherapy regimens fornon-small cell lung cancer. Cochrane Database Syst Rev 2001; CD002143.
12. Lester JF, Macbeth FR, Toy E, et al. Palliative radiotherapy regimens for non-small cell lung cancer. Cochrane Database Syst Rev 2006; CD002143.
13. Fairchild A, Harris K, Barnes E, et al. Palliative thoracic radiotherapy for lung cancer: a systematic review. J Clin Oncol 2008;26:4001-4011.
14. Vokes EE, Herndon JE II, Crawford J, et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol 2002;20:4191-4198.
15. Dehing-Oberije C, De Ruysscher D, van Baardwijk A, et al. The importance of patient characteristics for the prediction of radiation- induced lung toxicity. Radiother Oncol 2009;91:421-426.
16. Kwa SL, Lebesque JV, Theuws JC, et al. Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients. Int JRadiat Oncol Biol Phys 1998;42:1-9.
17. Nestle U, Nieder C, Walter K, et al. A palliative accelerated irradiation regimen for advanced non-small-cell lung cancer vs. conventionally fractionated 60 GY: results of a randomized equivalence study. Int J Radiat Oncol Biol Phys 2000;48:95-103.
18. Zatloukal P, Petruzelka L, Zemanova M, et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 2004;46:87-98.
19. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999;17:2692-2699.
20. Curran WJ, Scott CB, Langer CJ, et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410. J Clin Oncol 2003;22 (suppl; abstr 2499):621.
21. van den Hout WB, Kramer GW, Noordijk EM, et al. Cost-utility analysis of short-versus long-course palliative radiotherapy in patients with non-small cell lung cancer. J Natl Cancer Inst 2006;98:1786-1794.